Our use of cookies

We use necessary cookies to make our site work.

For more detailed information about the cookies we use, see our Cookie Policy.


Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Otsuka in Europe

Welcome to Otsuka in Europe

Otsuka Pharmaceutical Europe Ltd. (OPEL) is the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., which was founded in Japan in 1921. In Europe, we may be geographically distant from our roots, but we still hold true to the Japanese principles of ‘Ryukan-godo’, ‘Jissho’ and ‘Sosozei’. This means that every day we strive to channel our passion and commitment into improving the health of our patients.
Ryukan-godo
"By sweat we recognise the way"
Jissho
"Actualisation"
Sozosei
"Creativity"

Our European story

Otsuka expanded its pharmaceutical business into Europe in 1974 with the opening of a representative European office in Italy and subsequently invested in Laboratorios Miquel S.A. of Spain. Laboratorios Miquel S.A. became our first operating company in Europe. Otsuka Pharmaceutical Europe Ltd. (OPEL) was established in the U.K. in 1997 as Otsuka’s European regional office, and across Europe we now employ around 550 people. We focus on some of Europe’s most serious health challenges in neuroscience, nephrology, haemato-oncology and endocrinology. We are also exploring how digital health technology may provide holistic health solutions for patients, carers and healthcare professionals.  Core functions of sales and marketing, medical and access are present in our affiliate offices across Europe and are supported by OPEL. For other European countries, Otsuka products are managed through a number of partnerships and distributors, ensuring wide European coverage. In 2014, the regional OPEL office moved to larger premises just outside London in Wexham. The rural location of our offices reflects our philosophy of taking ‘the road less travelled’ and has been designed to maximise the use of space, encourage the cross-fertilisation of ideas and help employees live and harness our values of integrity, compassion, collaboration, excellence and creativity. 

Otsuka Europe Development and Commercialisation Limited (OEDC) and Otsuka Pharmaceutical Development & Commercialisation Europe GmbH (ODCE)

OEDC was established in July 2013 in Wexham, UK. ODCE was established in December 2018 in Frankfurt, Germany. OEDC and ODCE are fully integrated in the global Otsuka organisation and in Europe, are supporting OPEL, its affiliates, and ONPG. The two companies, OEDC and ODCE, focus on Regulatory Affairs, Pharmacovigilance, Global Quality Management and Clinical Development. We work in close collaboration with OPEL towards the successful development and uptake of Otsuka’s products in Europe. Together, we are focusing on some of the world’s unresolved health issues in some of the most challenging conditions of the body and mind.

Otsuka Novel Products GmbH (ONPG)

ONPG, based in Munich, is dedicated to addressing challenges from infectious diseases such as Tuberculosis (TB). Our colleagues at ONPG work closely in consultation with public health experts, patient organisations and health authorities to develop solutions in this field and to support public health strategies.

Collaborations and alliances—building relationships and working together

Otsuka’s global family also consists of a number of different companies with varied portfolios and therapy areas, allowing us to offer wide ranging support to our patients and their carers.   In Europe we have built relationships with like-minded pharmaceutical companies and other organisations who share our commitment to delivering medicines to the people who need them. We believe that by pooling resources and expertise and by working as a team with those who share our passion and goals, we can accelerate this process.

Discover Otsuka in Europe

Date of preparation: January 2021 | Reference NOR-NPR-2100001

This website is for all those with an interest in Otsuka Pharmaceutical in the Nordics and BeNeLux.